REFERENCES
- Anderson KS. Perspectives on the molecular mechanism of inhibition and toxicity of nucleoside analogs that tar-get HIV-1 reverse transcriptase. Biochim Biophys Acta. 2002;1587(2-3):296–299.
- Piliero PJ. Pharmacokinetic properties of nucleoside/ nucleotide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2004;37(Suppl 1):S2–S12.
- Flynn PM, Rodman J, Lindsey JC, et al. Intracellular phar-macokinetics of once versus twice daily zidovudine and lamivudine in adolescents. Antimicrob Agents Chemother 2007;51(10):3516–3522.
- Yuen GJ, Lou Y, Bumgarner NF, et al. Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivu-dine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrob Agents Chemother 2004;48:176–182.
- Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 198147: 207–214.
- Bruno R, Regazzi MB, Ciappina V, et al. Comparison of the plasma pharmacokinetics of lamivudine during twice and once daily administration in patients with HIV. Clin Pharmacokinet. 2001;40:695–700.
- Panhard X, Legrand M, Taburet AM, et al. Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV infected patients on HAART. Eur J Clin Pharmacol. 2007;63:1019–1029.
- Donnerer J, Haas BJ, Kessler HH. Single-measurement therapeutic drug monitoring of the HIV/AIDS drugs aba-cavir, zidovudine, lamivudine, efavirenz, nevirapine, lopine-vir and nelfinavir. Pharmacology. 2008;82:287–292.
- Coates JA, Cammack N, Jenkinson HJ, et al. The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob Agents Chemother. 1992;36:202–205.
- Soudeyns H, Yao XI, Gao Q, et al. Anti-human immu-nodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocy-clic nucleoside analog. Antimicrob Agents Chemother. 1991;35:1386–1390.
- Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Clini-cal pharmacokinetics of lamivudine. Clin Pharmacokinet. 1999;36(1):41–66.
- Johnson MA, Verpooten GA, Daniel MJ, et al. Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis. Br J Clin Pharmacol. 1998;46:21–27.
- Bohjanen PR, Johnson MD, Szczech LA, et al. Steady-state pharmacokinetics of lamivudine in human immu-nodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis. Antimicrob Agents Chemother 2002;46: 2387–2392.
- Johnson MA, Horak J, Breuel P. The pharmacokinetics of lamivudine in patients with impaired hepatic function. Eur J Clin Pharmacol. 1998;54:363–366.
- Moore JD, Acosta EP, Johnson VA, et al. Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy. Antivir Ther 2007;12:981–986.
- Gray NM, Marr CL, Penn CR, et al. The intracellular phos-phorylation of (-)-2'-deoxy-3'-thiacytidine (3TC) and the incorporation of 3TC 5'-monophosphate into DNA by HIV-1 reverse transcriptase and human DNA polymerase gamma. Biochem Pharmacol. 1995;50:1043–1051.
- Moore KH, Barrett JE, Shaw S, et al. The pharmacoki-netics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS. 1999;13:2239–2250.
- Fletcher CV, Kawle SP, Kakuda TN, et al. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS. 2000;14:2137–2144.